Guth et al. showed in the TRAMPC1 genetic mouse model of prostate cancer that ranolazine (i) suppressed tumour growth and (ii) stimulated anti-cancer immunity measured by decreased tumour CD8 + T-cells Tim3 content, increased macrophages and decreased blood myeloid immunosuppressive monocytes [38]. Here, CD8A is linked to neoplasm.